| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine-Related Disorders | 75 | 2020 | 504 | 10.500 |
Why?
|
| Substance-Related Disorders | 100 | 2022 | 1242 | 9.510 |
Why?
|
| Opioid-Related Disorders | 35 | 2022 | 298 | 7.590 |
Why?
|
| Stress Disorders, Post-Traumatic | 72 | 2023 | 1506 | 6.300 |
Why?
|
| Alcoholism | 74 | 2023 | 1109 | 5.720 |
Why?
|
| Analgesics, Opioid | 22 | 2022 | 498 | 5.270 |
Why?
|
| Cues | 42 | 2021 | 654 | 5.130 |
Why?
|
| Stress, Psychological | 32 | 2022 | 824 | 4.100 |
Why?
|
| Behavior, Addictive | 22 | 2017 | 317 | 3.700 |
Why?
|
| Adult | 248 | 2022 | 21403 | 3.560 |
Why?
|
| Tobacco Use Disorder | 22 | 2020 | 432 | 3.340 |
Why?
|
| Hydrocortisone | 25 | 2022 | 291 | 3.240 |
Why?
|
| Buprenorphine | 8 | 2021 | 67 | 3.200 |
Why?
|
| Humans | 369 | 2023 | 68618 | 3.040 |
Why?
|
| Female | 272 | 2022 | 38074 | 2.920 |
Why?
|
| Male | 273 | 2022 | 37321 | 2.880 |
Why?
|
| Marijuana Abuse | 12 | 2015 | 251 | 2.710 |
Why?
|
| Sex Characteristics | 14 | 2020 | 295 | 2.550 |
Why?
|
| Anxiety Disorders | 27 | 2016 | 426 | 2.540 |
Why?
|
| Amphetamine-Related Disorders | 10 | 2013 | 92 | 2.440 |
Why?
|
| Bipolar Disorder | 26 | 2014 | 307 | 2.360 |
Why?
|
| Cocaine | 25 | 2022 | 555 | 2.340 |
Why?
|
| Craving | 14 | 2022 | 200 | 2.280 |
Why?
|
| Oxytocin | 12 | 2023 | 124 | 2.200 |
Why?
|
| Implosive Therapy | 8 | 2022 | 171 | 2.170 |
Why?
|
| Brain | 21 | 2021 | 2176 | 2.160 |
Why?
|
| Mental Disorders | 22 | 2022 | 659 | 2.140 |
Why?
|
| Substance Withdrawal Syndrome | 19 | 2015 | 435 | 2.070 |
Why?
|
| Comorbidity | 76 | 2019 | 1426 | 2.010 |
Why?
|
| Prescription Drugs | 6 | 2017 | 71 | 1.950 |
Why?
|
| Double-Blind Method | 47 | 2023 | 1738 | 1.910 |
Why?
|
| Life Change Events | 12 | 2013 | 223 | 1.910 |
Why?
|
| Veterans | 11 | 2023 | 904 | 1.850 |
Why?
|
| Adolescent | 83 | 2020 | 8912 | 1.810 |
Why?
|
| Middle Aged | 129 | 2020 | 21147 | 1.790 |
Why?
|
| Adrenocorticotropic Hormone | 11 | 2011 | 106 | 1.770 |
Why?
|
| Pituitary-Adrenal System | 16 | 2022 | 138 | 1.760 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2021 | 2223 | 1.720 |
Why?
|
| Smoking | 19 | 2020 | 1452 | 1.680 |
Why?
|
| Cycloserine | 4 | 2015 | 30 | 1.650 |
Why?
|
| Drug Overdose | 5 | 2021 | 67 | 1.630 |
Why?
|
| Motivation | 17 | 2021 | 561 | 1.610 |
Why?
|
| Young Adult | 54 | 2021 | 5717 | 1.570 |
Why?
|
| Smoking Cessation | 13 | 2020 | 1034 | 1.540 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 30 | 2018 | 151 | 1.480 |
Why?
|
| Sertraline | 13 | 2012 | 62 | 1.460 |
Why?
|
| Corticotropin-Releasing Hormone | 6 | 2017 | 79 | 1.450 |
Why?
|
| Hypothalamo-Hypophyseal System | 15 | 2022 | 150 | 1.410 |
Why?
|
| Psychiatric Status Rating Scales | 38 | 2013 | 782 | 1.410 |
Why?
|
| Arousal | 10 | 2015 | 168 | 1.370 |
Why?
|
| Opiate Substitution Treatment | 7 | 2021 | 57 | 1.370 |
Why?
|
| Mood Disorders | 12 | 2015 | 132 | 1.310 |
Why?
|
| Substance Abuse, Intravenous | 4 | 2019 | 30 | 1.310 |
Why?
|
| Anxiety | 10 | 2017 | 422 | 1.300 |
Why?
|
| Chronic Pain | 4 | 2020 | 110 | 1.300 |
Why?
|
| Narcotic Antagonists | 6 | 2020 | 184 | 1.270 |
Why?
|
| Impulsive Behavior | 6 | 2016 | 85 | 1.260 |
Why?
|
| Cannabis | 5 | 2020 | 115 | 1.260 |
Why?
|
| Substance Abuse Detection | 10 | 2015 | 66 | 1.250 |
Why?
|
| Neurofeedback | 5 | 2016 | 34 | 1.240 |
Why?
|
| Extinction, Psychological | 5 | 2023 | 240 | 1.240 |
Why?
|
| Stress, Physiological | 7 | 2012 | 215 | 1.240 |
Why?
|
| Treatment Outcome | 56 | 2023 | 7029 | 1.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2019 | 767 | 1.170 |
Why?
|
| Sex Factors | 23 | 2019 | 1266 | 1.160 |
Why?
|
| Child Abuse | 11 | 2015 | 186 | 1.140 |
Why?
|
| Yohimbine | 3 | 2017 | 41 | 1.130 |
Why?
|
| Valproic Acid | 11 | 2003 | 93 | 1.100 |
Why?
|
| Psychotherapy | 13 | 2020 | 253 | 1.080 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2020 | 468 | 1.070 |
Why?
|
| Pilot Projects | 26 | 2019 | 1342 | 1.060 |
Why?
|
| Heart Rate | 11 | 2019 | 568 | 1.000 |
Why?
|
| Alcohol-Related Disorders | 5 | 2016 | 95 | 0.990 |
Why?
|
| Psychiatry | 6 | 2022 | 112 | 0.990 |
Why?
|
| HIV Infections | 8 | 2021 | 791 | 0.990 |
Why?
|
| Functional Neuroimaging | 7 | 2018 | 82 | 0.970 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2019 | 504 | 0.950 |
Why?
|
| United States | 44 | 2022 | 7367 | 0.950 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 10 | 2010 | 189 | 0.940 |
Why?
|
| Surveys and Questionnaires | 26 | 2022 | 2800 | 0.930 |
Why?
|
| Personality Inventory | 11 | 2012 | 197 | 0.910 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 101 | 0.900 |
Why?
|
| Depressive Disorder | 15 | 2018 | 621 | 0.880 |
Why?
|
| Anti-Anxiety Agents | 8 | 2009 | 107 | 0.880 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 18 | 2020 | 257 | 0.880 |
Why?
|
| Pain Management | 5 | 2019 | 186 | 0.880 |
Why?
|
| Prescription Drug Misuse | 5 | 2015 | 35 | 0.870 |
Why?
|
| Methamphetamine | 5 | 2013 | 132 | 0.870 |
Why?
|
| Anticonvulsants | 11 | 2002 | 223 | 0.850 |
Why?
|
| Biomedical Research | 8 | 2020 | 310 | 0.850 |
Why?
|
| Mindfulness | 2 | 2021 | 41 | 0.840 |
Why?
|
| Acetylcysteine | 5 | 2018 | 296 | 0.840 |
Why?
|
| Pregnant Women | 2 | 2020 | 50 | 0.830 |
Why?
|
| Alcohol Drinking | 16 | 2022 | 805 | 0.820 |
Why?
|
| Prescription Drug Monitoring Programs | 3 | 2018 | 34 | 0.820 |
Why?
|
| Health Personnel | 2 | 2019 | 286 | 0.810 |
Why?
|
| Secondary Prevention | 12 | 2021 | 291 | 0.750 |
Why?
|
| Cities | 2 | 2017 | 29 | 0.730 |
Why?
|
| Buspirone | 7 | 2015 | 36 | 0.730 |
Why?
|
| Medical Marijuana | 1 | 2020 | 21 | 0.720 |
Why?
|
| Ketamine | 4 | 2019 | 57 | 0.720 |
Why?
|
| Gyrus Cinguli | 4 | 2016 | 113 | 0.710 |
Why?
|
| Practice Patterns, Dentists' | 2 | 2019 | 10 | 0.700 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 711 | 0.700 |
Why?
|
| Affect | 7 | 2012 | 218 | 0.700 |
Why?
|
| Prevalence | 30 | 2017 | 1619 | 0.700 |
Why?
|
| Prescription Drug Diversion | 2 | 2019 | 7 | 0.700 |
Why?
|
| Fear | 4 | 2023 | 239 | 0.690 |
Why?
|
| Clinical Trials as Topic | 7 | 2013 | 848 | 0.690 |
Why?
|
| Cold Temperature | 5 | 2006 | 90 | 0.690 |
Why?
|
| Prefrontal Cortex | 11 | 2020 | 640 | 0.670 |
Why?
|
| Crack Cocaine | 4 | 2006 | 20 | 0.670 |
Why?
|
| Age of Onset | 8 | 2012 | 188 | 0.660 |
Why?
|
| Internship and Residency | 4 | 2022 | 596 | 0.660 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 29 | 0.650 |
Why?
|
| Galvanic Skin Response | 7 | 2018 | 67 | 0.640 |
Why?
|
| Progesterone | 3 | 2020 | 115 | 0.640 |
Why?
|
| Needs Assessment | 2 | 2019 | 186 | 0.640 |
Why?
|
| Time Factors | 16 | 2020 | 4655 | 0.630 |
Why?
|
| Cognition Disorders | 2 | 2012 | 342 | 0.630 |
Why?
|
| Pain | 5 | 2020 | 472 | 0.630 |
Why?
|
| Program Development | 3 | 2019 | 240 | 0.630 |
Why?
|
| Naltrexone | 7 | 2007 | 195 | 0.620 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 2 | 2017 | 15 | 0.620 |
Why?
|
| Dentists | 3 | 2019 | 18 | 0.610 |
Why?
|
| Nicotine | 5 | 2020 | 350 | 0.610 |
Why?
|
| Couples Therapy | 1 | 2017 | 10 | 0.610 |
Why?
|
| Negotiating | 1 | 2017 | 18 | 0.610 |
Why?
|
| Taurine | 4 | 2012 | 51 | 0.600 |
Why?
|
| South Carolina | 13 | 2021 | 2752 | 0.600 |
Why?
|
| Cross-Sectional Studies | 19 | 2019 | 2279 | 0.590 |
Why?
|
| Community Mental Health Services | 3 | 2015 | 65 | 0.590 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 136 | 0.580 |
Why?
|
| Oxycodone | 1 | 2017 | 10 | 0.580 |
Why?
|
| Age Factors | 15 | 2015 | 1864 | 0.570 |
Why?
|
| Psychological Tests | 6 | 2013 | 96 | 0.570 |
Why?
|
| Norepinephrine | 2 | 2017 | 276 | 0.560 |
Why?
|
| Psychotropic Drugs | 7 | 2018 | 83 | 0.560 |
Why?
|
| Child | 28 | 2020 | 6405 | 0.560 |
Why?
|
| Depression | 12 | 2021 | 943 | 0.560 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 3259 | 0.550 |
Why?
|
| Ethanol | 6 | 2014 | 893 | 0.550 |
Why?
|
| Schizophrenia | 7 | 2020 | 206 | 0.550 |
Why?
|
| Aged | 36 | 2020 | 14862 | 0.540 |
Why?
|
| Alcohol Deterrents | 5 | 2012 | 86 | 0.540 |
Why?
|
| Women's Health | 4 | 2019 | 148 | 0.540 |
Why?
|
| Research Subjects | 3 | 2013 | 45 | 0.540 |
Why?
|
| Socioeconomic Factors | 14 | 2017 | 955 | 0.530 |
Why?
|
| Military Personnel | 1 | 2018 | 221 | 0.530 |
Why?
|
| Saliva | 9 | 2022 | 142 | 0.530 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2020 | 52 | 0.530 |
Why?
|
| Health Policy | 2 | 2017 | 221 | 0.530 |
Why?
|
| Research Personnel | 4 | 2020 | 83 | 0.510 |
Why?
|
| Reward | 3 | 2021 | 201 | 0.510 |
Why?
|
| Emotions | 7 | 2019 | 244 | 0.510 |
Why?
|
| Analysis of Variance | 13 | 2013 | 1040 | 0.510 |
Why?
|
| Antidepressive Agents | 7 | 2012 | 216 | 0.510 |
Why?
|
| Marijuana Smoking | 3 | 2015 | 108 | 0.500 |
Why?
|
| Recurrence | 10 | 2021 | 948 | 0.500 |
Why?
|
| Pregnancy Complications | 4 | 2017 | 286 | 0.500 |
Why?
|
| Electronic Health Records | 5 | 2022 | 374 | 0.500 |
Why?
|
| Adoption | 1 | 2015 | 11 | 0.500 |
Why?
|
| Transcranial Magnetic Stimulation | 5 | 2020 | 413 | 0.500 |
Why?
|
| Growth Disorders | 1 | 2015 | 21 | 0.490 |
Why?
|
| Carbamazepine | 7 | 2002 | 108 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 772 | 0.490 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 214 | 0.490 |
Why?
|
| Drug-Seeking Behavior | 3 | 2017 | 213 | 0.490 |
Why?
|
| Psychotic Disorders | 4 | 2011 | 157 | 0.480 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2013 | 689 | 0.480 |
Why?
|
| Guideline Adherence | 1 | 2017 | 287 | 0.480 |
Why?
|
| Memory | 2 | 2013 | 214 | 0.480 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2007 | 60 | 0.480 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 581 | 0.480 |
Why?
|
| Rural Population | 3 | 2019 | 398 | 0.470 |
Why?
|
| Mass Screening | 7 | 2020 | 843 | 0.470 |
Why?
|
| Sex Offenses | 4 | 2022 | 170 | 0.470 |
Why?
|
| Amines | 3 | 2007 | 98 | 0.460 |
Why?
|
| Photic Stimulation | 7 | 2016 | 229 | 0.460 |
Why?
|
| Substance Abuse Treatment Centers | 8 | 2015 | 71 | 0.460 |
Why?
|
| Attention | 1 | 2016 | 225 | 0.460 |
Why?
|
| Benzodiazepines | 4 | 2012 | 130 | 0.460 |
Why?
|
| Quinoxalines | 2 | 2015 | 78 | 0.450 |
Why?
|
| Propylamines | 2 | 2010 | 22 | 0.450 |
Why?
|
| Estrogens | 1 | 2014 | 173 | 0.450 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2010 | 20 | 0.450 |
Why?
|
| Patient Education as Topic | 3 | 2013 | 425 | 0.450 |
Why?
|
| Benzazepines | 2 | 2015 | 104 | 0.440 |
Why?
|
| Antimetabolites | 1 | 2013 | 17 | 0.440 |
Why?
|
| Psychomotor Performance | 3 | 2013 | 213 | 0.430 |
Why?
|
| Pregnancy | 10 | 2021 | 2334 | 0.430 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2007 | 208 | 0.430 |
Why?
|
| Pergolide | 3 | 2003 | 12 | 0.430 |
Why?
|
| Propranolol | 1 | 2013 | 103 | 0.430 |
Why?
|
| Social Work | 1 | 2013 | 27 | 0.420 |
Why?
|
| Physicians | 3 | 2022 | 324 | 0.420 |
Why?
|
| Risk Factors | 22 | 2018 | 5731 | 0.420 |
Why?
|
| Developmental Disabilities | 2 | 2015 | 119 | 0.420 |
Why?
|
| Combined Modality Therapy | 10 | 2016 | 951 | 0.420 |
Why?
|
| Patient Selection | 4 | 2013 | 592 | 0.420 |
Why?
|
| Ambulatory Care | 11 | 2012 | 340 | 0.410 |
Why?
|
| Nerve Net | 3 | 2018 | 181 | 0.410 |
Why?
|
| Central Nervous System Stimulants | 5 | 2013 | 221 | 0.410 |
Why?
|
| Phobic Disorders | 7 | 2008 | 227 | 0.400 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2012 | 85 | 0.400 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 128 | 0.400 |
Why?
|
| Affective Symptoms | 1 | 2012 | 50 | 0.400 |
Why?
|
| Social Behavior | 2 | 2015 | 164 | 0.390 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.390 |
Why?
|
| Prescriptions | 2 | 2021 | 28 | 0.390 |
Why?
|
| Antipsychotic Agents | 4 | 2008 | 247 | 0.380 |
Why?
|
| Nootropic Agents | 1 | 2011 | 18 | 0.380 |
Why?
|
| Severity of Illness Index | 18 | 2018 | 1851 | 0.380 |
Why?
|
| Violence | 4 | 2010 | 275 | 0.380 |
Why?
|
| Neurotic Disorders | 1 | 2011 | 13 | 0.380 |
Why?
|
| Faculty, Medical | 3 | 2022 | 110 | 0.370 |
Why?
|
| Genetic Linkage | 5 | 2010 | 90 | 0.370 |
Why?
|
| Models, Statistical | 3 | 2011 | 448 | 0.370 |
Why?
|
| Racism | 2 | 2022 | 59 | 0.370 |
Why?
|
| Depressive Disorder, Major | 2 | 2013 | 439 | 0.360 |
Why?
|
| Cognition | 2 | 2011 | 513 | 0.360 |
Why?
|
| Vigabatrin | 2 | 2009 | 8 | 0.360 |
Why?
|
| Education | 1 | 2011 | 83 | 0.360 |
Why?
|
| Social Environment | 3 | 2010 | 182 | 0.360 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2019 | 109 | 0.360 |
Why?
|
| Association Learning | 1 | 2010 | 36 | 0.360 |
Why?
|
| Patient Compliance | 8 | 2015 | 402 | 0.350 |
Why?
|
| Personality Disorders | 5 | 2015 | 44 | 0.350 |
Why?
|
| Case-Control Studies | 11 | 2016 | 1553 | 0.350 |
Why?
|
| Research | 2 | 2011 | 214 | 0.350 |
Why?
|
| Research Support as Topic | 3 | 2020 | 58 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 1085 | 0.340 |
Why?
|
| Cross-Over Studies | 5 | 2016 | 260 | 0.340 |
Why?
|
| Referral and Consultation | 4 | 2021 | 383 | 0.340 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 135 | 0.340 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 334 | 0.340 |
Why?
|
| Administration, Intranasal | 6 | 2021 | 88 | 0.340 |
Why?
|
| Drug Prescriptions | 2 | 2010 | 135 | 0.330 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 60 | 0.330 |
Why?
|
| Paralysis | 1 | 2009 | 35 | 0.320 |
Why?
|
| Drug Therapy | 2 | 2006 | 71 | 0.320 |
Why?
|
| Restraint, Physical | 1 | 2009 | 59 | 0.320 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 21 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 931 | 0.320 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.320 |
Why?
|
| Paranoid Disorders | 6 | 2011 | 9 | 0.320 |
Why?
|
| Patient Care | 1 | 2009 | 61 | 0.310 |
Why?
|
| Cannabinoids | 5 | 2015 | 90 | 0.310 |
Why?
|
| Mother-Child Relations | 2 | 2016 | 43 | 0.310 |
Why?
|
| Child, Preschool | 7 | 2021 | 3187 | 0.310 |
Why?
|
| Piperazines | 3 | 2008 | 206 | 0.310 |
Why?
|
| Brain Mapping | 5 | 2015 | 532 | 0.310 |
Why?
|
| Hospitalization | 11 | 2018 | 978 | 0.300 |
Why?
|
| Triglycerides | 1 | 2008 | 184 | 0.300 |
Why?
|
| Quinolones | 1 | 2008 | 60 | 0.300 |
Why?
|
| Panic Disorder | 5 | 2008 | 121 | 0.300 |
Why?
|
| Psychology, Child | 1 | 2007 | 28 | 0.300 |
Why?
|
| Internet | 3 | 2015 | 390 | 0.300 |
Why?
|
| Multicenter Studies as Topic | 3 | 2016 | 186 | 0.300 |
Why?
|
| Physical Therapy Modalities | 1 | 2009 | 133 | 0.300 |
Why?
|
| Blood Pressure | 3 | 2015 | 1451 | 0.300 |
Why?
|
| Behavior Therapy | 1 | 2010 | 297 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2011 | 786 | 0.290 |
Why?
|
| Prospective Studies | 8 | 2019 | 3705 | 0.280 |
Why?
|
| Health Status | 2 | 2007 | 429 | 0.280 |
Why?
|
| Aggression | 3 | 2011 | 98 | 0.280 |
Why?
|
| Touch | 1 | 2006 | 25 | 0.280 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2009 | 266 | 0.280 |
Why?
|
| Menstrual Cycle | 1 | 2006 | 64 | 0.270 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2007 | 91 | 0.270 |
Why?
|
| Antimanic Agents | 3 | 2003 | 21 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2011 | 627 | 0.270 |
Why?
|
| Social Support | 3 | 2020 | 423 | 0.260 |
Why?
|
| Dehydroepiandrosterone | 3 | 2015 | 29 | 0.260 |
Why?
|
| Patient Dropouts | 3 | 2018 | 98 | 0.260 |
Why?
|
| Residential Treatment | 2 | 2008 | 24 | 0.260 |
Why?
|
| Tobacco | 1 | 2006 | 161 | 0.260 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 442 | 0.260 |
Why?
|
| Philadelphia | 3 | 2020 | 18 | 0.250 |
Why?
|
| Stochastic Processes | 1 | 2005 | 27 | 0.250 |
Why?
|
| Suicide, Attempted | 3 | 2014 | 72 | 0.250 |
Why?
|
| Feasibility Studies | 6 | 2015 | 652 | 0.250 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2005 | 22 | 0.250 |
Why?
|
| Sleep | 2 | 2013 | 263 | 0.250 |
Why?
|
| Phencyclidine | 7 | 1984 | 17 | 0.240 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 3 | 2006 | 19 | 0.240 |
Why?
|
| Risk Assessment | 2 | 2017 | 2007 | 0.230 |
Why?
|
| Serotonin Receptor Agonists | 2 | 2015 | 34 | 0.230 |
Why?
|
| Dopamine Agonists | 2 | 2003 | 68 | 0.230 |
Why?
|
| Adult Survivors of Child Abuse | 2 | 2015 | 20 | 0.230 |
Why?
|
| Weight Gain | 3 | 2008 | 135 | 0.230 |
Why?
|
| Diagnosis, Differential | 8 | 2005 | 1140 | 0.220 |
Why?
|
| Nicotinic Agonists | 3 | 2015 | 111 | 0.220 |
Why?
|
| Adaptation, Psychological | 4 | 2015 | 447 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4848 | 0.220 |
Why?
|
| Financing, Organized | 2 | 2020 | 21 | 0.220 |
Why?
|
| Cluster Analysis | 5 | 2012 | 219 | 0.210 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2023 | 20 | 0.210 |
Why?
|
| Doxazosin | 2 | 2023 | 20 | 0.210 |
Why?
|
| Risk-Taking | 4 | 2017 | 210 | 0.210 |
Why?
|
| Placebos | 7 | 2017 | 195 | 0.210 |
Why?
|
| Research Design | 6 | 2016 | 729 | 0.210 |
Why?
|
| Adolescent Behavior | 2 | 2019 | 264 | 0.210 |
Why?
|
| Linear Models | 3 | 2013 | 521 | 0.210 |
Why?
|
| Pain Measurement | 5 | 2020 | 328 | 0.210 |
Why?
|
| Animals | 18 | 2018 | 20881 | 0.210 |
Why?
|
| Imipramine | 2 | 1994 | 44 | 0.210 |
Why?
|
| Imagination | 3 | 2012 | 38 | 0.210 |
Why?
|
| Spinal Cord Injuries | 1 | 2009 | 551 | 0.210 |
Why?
|
| Prisoners | 2 | 2000 | 50 | 0.200 |
Why?
|
| Informed Consent | 2 | 2013 | 127 | 0.200 |
Why?
|
| Predictive Value of Tests | 5 | 2011 | 1465 | 0.200 |
Why?
|
| Cooperative Behavior | 3 | 2016 | 235 | 0.200 |
Why?
|
| Acetates | 2 | 2001 | 74 | 0.200 |
Why?
|
| Self Report | 3 | 2015 | 371 | 0.200 |
Why?
|
| Clonidine | 1 | 2021 | 66 | 0.200 |
Why?
|
| Life Expectancy | 1 | 2021 | 51 | 0.200 |
Why?
|
| Mentoring | 1 | 2022 | 53 | 0.190 |
Why?
|
| Natural Language Processing | 1 | 2022 | 69 | 0.190 |
Why?
|
| Somatoform Disorders | 4 | 1997 | 35 | 0.190 |
Why?
|
| Homosexuality, Male | 2 | 2020 | 34 | 0.190 |
Why?
|
| Interpersonal Relations | 3 | 2018 | 209 | 0.190 |
Why?
|
| Inpatients | 2 | 2003 | 208 | 0.190 |
Why?
|
| Single Parent | 1 | 2000 | 2 | 0.180 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2017 | 73 | 0.180 |
Why?
|
| Child of Impaired Parents | 1 | 2000 | 18 | 0.180 |
Why?
|
| Emergency Treatment | 2 | 2001 | 52 | 0.180 |
Why?
|
| Primary Health Care | 5 | 2017 | 703 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 77 | 0.180 |
Why?
|
| Aftercare | 5 | 2016 | 114 | 0.180 |
Why?
|
| Students, Medical | 2 | 2014 | 210 | 0.180 |
Why?
|
| Child Behavior | 1 | 2000 | 56 | 0.180 |
Why?
|
| Psychoses, Substance-Induced | 3 | 1999 | 20 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 26 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2018 | 107 | 0.180 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Rape | 1 | 2001 | 180 | 0.180 |
Why?
|
| Sexual Partners | 2 | 2018 | 106 | 0.180 |
Why?
|
| Nausea | 1 | 2000 | 47 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 51 | 0.170 |
Why?
|
| Obsessive-Compulsive Disorder | 4 | 2008 | 88 | 0.170 |
Why?
|
| Antidepressive Agents, Second-Generation | 4 | 2004 | 54 | 0.170 |
Why?
|
| Logistic Models | 6 | 2012 | 1420 | 0.170 |
Why?
|
| Ovary | 1 | 2020 | 99 | 0.170 |
Why?
|
| Needle-Exchange Programs | 1 | 2019 | 1 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2010 | 10 | 0.170 |
Why?
|
| Interdisciplinary Research | 1 | 2019 | 4 | 0.170 |
Why?
|
| Mental Health Services | 2 | 2020 | 199 | 0.170 |
Why?
|
| Smoking Prevention | 4 | 2015 | 259 | 0.170 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 23 | 0.170 |
Why?
|
| 1-Naphthylamine | 2 | 1997 | 11 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.170 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 517 | 0.170 |
Why?
|
| Treatment Failure | 2 | 2015 | 216 | 0.170 |
Why?
|
| Cerebellum | 1 | 2020 | 103 | 0.160 |
Why?
|
| Analgesics | 1 | 2020 | 118 | 0.160 |
Why?
|
| Quality of Life | 6 | 2021 | 1515 | 0.160 |
Why?
|
| Regression Analysis | 6 | 2008 | 737 | 0.160 |
Why?
|
| Oxytocics | 1 | 2018 | 14 | 0.160 |
Why?
|
| Fellowships and Scholarships | 3 | 2022 | 127 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2003 | 1745 | 0.160 |
Why?
|
| Poisson Distribution | 2 | 2011 | 85 | 0.160 |
Why?
|
| Discrimination Learning | 4 | 1982 | 45 | 0.160 |
Why?
|
| Education, Dental | 1 | 2019 | 63 | 0.160 |
Why?
|
| Genetic Variation | 3 | 2009 | 220 | 0.160 |
Why?
|
| Career Choice | 3 | 2019 | 98 | 0.160 |
Why?
|
| Crime | 2 | 1997 | 53 | 0.160 |
Why?
|
| Demography | 5 | 2011 | 279 | 0.160 |
Why?
|
| Sexism | 1 | 2018 | 11 | 0.160 |
Why?
|
| Self Care | 1 | 2021 | 253 | 0.160 |
Why?
|
| Foundations | 1 | 2018 | 17 | 0.150 |
Why?
|
| Temperance | 3 | 2007 | 41 | 0.150 |
Why?
|
| Suicide | 2 | 2014 | 116 | 0.150 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 79 | 0.150 |
Why?
|
| Education, Medical | 1 | 2019 | 147 | 0.150 |
Why?
|
| Pandemics | 1 | 2021 | 352 | 0.150 |
Why?
|
| Paraproteinemias | 1 | 1997 | 4 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2021 | 403 | 0.150 |
Why?
|
| Acute Pain | 1 | 2018 | 35 | 0.150 |
Why?
|
| Feeding and Eating Disorders | 3 | 2010 | 106 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 319 | 0.150 |
Why?
|
| Mothers | 2 | 2016 | 172 | 0.150 |
Why?
|
| Retrospective Studies | 9 | 2020 | 7277 | 0.150 |
Why?
|
| Neuroimaging | 1 | 2018 | 122 | 0.150 |
Why?
|
| Executive Function | 1 | 2018 | 106 | 0.150 |
Why?
|
| Intimate Partner Violence | 1 | 2018 | 58 | 0.150 |
Why?
|
| Lorazepam | 2 | 2016 | 54 | 0.150 |
Why?
|
| Single-Blind Method | 4 | 2020 | 249 | 0.150 |
Why?
|
| Anti-Retroviral Agents | 1 | 2017 | 53 | 0.140 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 1998 | 45 | 0.140 |
Why?
|
| Gaucher Disease | 1 | 1997 | 60 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 1997 | 92 | 0.140 |
Why?
|
| Oxygen | 3 | 2013 | 386 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.140 |
Why?
|
| Lithium | 4 | 2000 | 76 | 0.140 |
Why?
|
| Caregivers | 1 | 2020 | 365 | 0.140 |
Why?
|
| Disulfiram | 1 | 2016 | 22 | 0.140 |
Why?
|
| Hydrocodone | 1 | 2016 | 5 | 0.140 |
Why?
|
| Australia | 4 | 2020 | 235 | 0.140 |
Why?
|
| Object Attachment | 1 | 2016 | 20 | 0.140 |
Why?
|
| Varenicline | 2 | 2015 | 98 | 0.130 |
Why?
|
| Antioxidants | 1 | 2018 | 304 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2009 | 714 | 0.130 |
Why?
|
| Methylphenidate | 2 | 2010 | 97 | 0.130 |
Why?
|
| Medical Informatics Applications | 1 | 2016 | 22 | 0.130 |
Why?
|
| Ethics Committees, Research | 1 | 2016 | 22 | 0.130 |
Why?
|
| Combat Disorders | 1 | 2016 | 102 | 0.130 |
Why?
|
| Social Networking | 1 | 2015 | 14 | 0.130 |
Why?
|
| Chromosome Mapping | 4 | 2010 | 188 | 0.130 |
Why?
|
| Age Distribution | 3 | 2015 | 320 | 0.130 |
Why?
|
| Counseling | 3 | 2012 | 280 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 85 | 0.130 |
Why?
|
| Individuality | 2 | 2012 | 44 | 0.130 |
Why?
|
| Haplotypes | 4 | 2009 | 174 | 0.130 |
Why?
|
| Fluvoxamine | 1 | 1994 | 22 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 1999 | 483 | 0.120 |
Why?
|
| Gender Identity | 1 | 2015 | 47 | 0.120 |
Why?
|
| Binge Drinking | 1 | 2015 | 50 | 0.120 |
Why?
|
| Thyroid Gland | 2 | 1994 | 67 | 0.120 |
Why?
|
| Qualitative Research | 2 | 2020 | 369 | 0.120 |
Why?
|
| Geography | 1 | 2015 | 80 | 0.120 |
Why?
|
| Learning | 2 | 2013 | 186 | 0.120 |
Why?
|
| Guanfacine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 11 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.120 |
Why?
|
| Motor Cortex | 2 | 2020 | 158 | 0.120 |
Why?
|
| Genotype | 7 | 2011 | 786 | 0.120 |
Why?
|
| Viral Load | 3 | 2021 | 127 | 0.120 |
Why?
|
| Mucin-1 | 3 | 1999 | 35 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 329 | 0.120 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 106 | 0.120 |
Why?
|
| Olfactory Perception | 1 | 2014 | 20 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 174 | 0.120 |
Why?
|
| Neural Pathways | 2 | 2014 | 324 | 0.120 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 415 | 0.120 |
Why?
|
| Gray Matter | 1 | 2014 | 57 | 0.120 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2011 | 31 | 0.120 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 2077 | 0.120 |
Why?
|
| Parietal Lobe | 1 | 2014 | 59 | 0.110 |
Why?
|
| Gene Frequency | 6 | 2010 | 207 | 0.110 |
Why?
|
| Atomoxetine Hydrochloride | 2 | 2010 | 14 | 0.110 |
Why?
|
| Self-Injurious Behavior | 2 | 2009 | 31 | 0.110 |
Why?
|
| Information Management | 1 | 2013 | 23 | 0.110 |
Why?
|
| Pediatric Obesity | 1 | 2015 | 92 | 0.110 |
Why?
|
| Nasal Sprays | 1 | 2013 | 11 | 0.110 |
Why?
|
| Videotape Recording | 1 | 2013 | 43 | 0.110 |
Why?
|
| Movement | 2 | 2013 | 179 | 0.110 |
Why?
|
| Body Temperature | 2 | 2012 | 116 | 0.110 |
Why?
|
| Drug Storage | 1 | 2013 | 16 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1054 | 0.110 |
Why?
|
| Dental Clinics | 1 | 2013 | 9 | 0.110 |
Why?
|
| Perception | 1 | 2014 | 189 | 0.110 |
Why?
|
| Models, Psychological | 2 | 2011 | 180 | 0.110 |
Why?
|
| Refuse Disposal | 1 | 2013 | 22 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2015 | 252 | 0.110 |
Why?
|
| Patient Preference | 1 | 2013 | 57 | 0.110 |
Why?
|
| Self Disclosure | 3 | 2002 | 55 | 0.110 |
Why?
|
| Markov Chains | 2 | 2011 | 133 | 0.110 |
Why?
|
| Reaction Time | 2 | 2012 | 170 | 0.100 |
Why?
|
| Amlodipine | 2 | 2005 | 31 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 237 | 0.100 |
Why?
|
| Physical Examination | 1 | 2013 | 152 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2014 | 403 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.100 |
Why?
|
| Clinical Competence | 2 | 2011 | 657 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.100 |
Why?
|
| Educational Status | 2 | 2011 | 273 | 0.100 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2012 | 32 | 0.100 |
Why?
|
| Calcium Channel Blockers | 2 | 2005 | 138 | 0.100 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 1 | 2011 | 19 | 0.100 |
Why?
|
| Tranylcypromine | 1 | 1991 | 8 | 0.100 |
Why?
|
| beta-Endorphin | 1 | 1991 | 15 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 3 | 1999 | 511 | 0.100 |
Why?
|
| Frontal Lobe | 1 | 2013 | 156 | 0.100 |
Why?
|
| Outpatients | 1 | 2012 | 127 | 0.100 |
Why?
|
| Adrenergic Agents | 1 | 2011 | 14 | 0.100 |
Why?
|
| Dynorphins | 1 | 1991 | 69 | 0.100 |
Why?
|
| Dominance, Cerebral | 1 | 2011 | 65 | 0.100 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2011 | 20 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2010 | 1753 | 0.100 |
Why?
|
| Crime Victims | 2 | 2005 | 286 | 0.100 |
Why?
|
| Health Surveys | 1 | 2013 | 489 | 0.100 |
Why?
|
| Reference Values | 3 | 2015 | 579 | 0.090 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2011 | 58 | 0.090 |
Why?
|
| Public Sector | 1 | 2010 | 19 | 0.090 |
Why?
|
| Motor Skills | 1 | 2011 | 88 | 0.090 |
Why?
|
| Benzhydryl Compounds | 1 | 2011 | 62 | 0.090 |
Why?
|
| Biofeedback, Psychology | 1 | 2010 | 23 | 0.090 |
Why?
|
| Autistic Disorder | 1 | 2012 | 77 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 102 | 0.090 |
Why?
|
| Personality | 1 | 2011 | 66 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 296 | 0.090 |
Why?
|
| Employment | 1 | 2011 | 154 | 0.090 |
Why?
|
| Task Performance and Analysis | 2 | 2010 | 150 | 0.090 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 250 | 0.090 |
Why?
|
| Evoked Potentials, Motor | 1 | 2010 | 63 | 0.090 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2010 | 11 | 0.090 |
Why?
|
| Behavior, Animal | 3 | 1984 | 470 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2009 | 307 | 0.090 |
Why?
|
| Scotoma | 1 | 2009 | 4 | 0.090 |
Why?
|
| Algorithms | 2 | 2006 | 1196 | 0.090 |
Why?
|
| Siblings | 2 | 2009 | 34 | 0.090 |
Why?
|
| Visual Fields | 1 | 2009 | 41 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2010 | 143 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2009 | 21 | 0.090 |
Why?
|
| GABA Agents | 2 | 2001 | 18 | 0.090 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 51 | 0.090 |
Why?
|
| Pain Clinics | 1 | 2009 | 8 | 0.090 |
Why?
|
| Alcohol Withdrawal Delirium | 2 | 2000 | 24 | 0.080 |
Why?
|
| Drug Approval | 1 | 2009 | 50 | 0.080 |
Why?
|
| Sample Size | 1 | 2009 | 79 | 0.080 |
Why?
|
| Mannosidases | 1 | 2009 | 4 | 0.080 |
Why?
|
| Pro-Opiomelanocortin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Thyroid Function Tests | 1 | 1989 | 21 | 0.080 |
Why?
|
| Family Health | 2 | 2006 | 83 | 0.080 |
Why?
|
| Ergometry | 1 | 2009 | 4 | 0.080 |
Why?
|
| Desipramine | 1 | 1989 | 47 | 0.080 |
Why?
|
| Fluoxetine | 1 | 1989 | 40 | 0.080 |
Why?
|
| Agoraphobia | 1 | 1989 | 59 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2009 | 94 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 131 | 0.080 |
Why?
|
| Random Allocation | 2 | 2018 | 442 | 0.080 |
Why?
|
| Conditioning, Operant | 5 | 1982 | 241 | 0.080 |
Why?
|
| Alleles | 4 | 2015 | 386 | 0.080 |
Why?
|
| Panic | 1 | 1989 | 97 | 0.080 |
Why?
|
| Muscular Atrophy | 1 | 2009 | 35 | 0.080 |
Why?
|
| Dissociative Disorders | 2 | 2000 | 16 | 0.080 |
Why?
|
| Nerve Regeneration | 1 | 2009 | 42 | 0.080 |
Why?
|
| Drug Industry | 1 | 2009 | 54 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2001 | 567 | 0.080 |
Why?
|
| Conflict of Interest | 1 | 2009 | 48 | 0.080 |
Why?
|
| Telephone | 2 | 2008 | 160 | 0.080 |
Why?
|
| Periodicity | 1 | 2008 | 43 | 0.080 |
Why?
|
| Aripiprazole | 1 | 2008 | 43 | 0.080 |
Why?
|
| Social Stigma | 2 | 2020 | 53 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 446 | 0.080 |
Why?
|
| Sexual Behavior | 2 | 2020 | 183 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 68 | 0.080 |
Why?
|
| Psychometrics | 4 | 1998 | 514 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.080 |
Why?
|
| Decision Making | 1 | 2011 | 410 | 0.080 |
Why?
|
| Control Groups | 1 | 2007 | 10 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 148 | 0.080 |
Why?
|
| Risperidone | 1 | 2008 | 48 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2009 | 239 | 0.080 |
Why?
|
| Neurologic Examination | 2 | 2006 | 107 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 981 | 0.080 |
Why?
|
| Manuals as Topic | 1 | 2007 | 8 | 0.070 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2007 | 19 | 0.070 |
Why?
|
| Spinal Cord | 1 | 2009 | 244 | 0.070 |
Why?
|
| Interview, Psychological | 3 | 2013 | 113 | 0.070 |
Why?
|
| Remote Consultation | 1 | 2008 | 50 | 0.070 |
Why?
|
| Mathematics | 1 | 2007 | 83 | 0.070 |
Why?
|
| Administration, Sublingual | 1 | 2007 | 15 | 0.070 |
Why?
|
| Risk | 1 | 2009 | 563 | 0.070 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2007 | 28 | 0.070 |
Why?
|
| Methadone | 1 | 2007 | 32 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2008 | 223 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 245 | 0.070 |
Why?
|
| Infant | 2 | 2016 | 2891 | 0.070 |
Why?
|
| Nipecotic Acids | 1 | 2007 | 11 | 0.070 |
Why?
|
| Electric Stimulation Therapy | 1 | 2009 | 147 | 0.070 |
Why?
|
| GABA Agonists | 1 | 2007 | 23 | 0.070 |
Why?
|
| Chi-Square Distribution | 4 | 2004 | 546 | 0.070 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2006 | 3 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 319 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2006 | 9 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 2006 | 31 | 0.070 |
Why?
|
| Dopa Decarboxylase | 1 | 2006 | 3 | 0.070 |
Why?
|
| Triazoles | 2 | 2004 | 43 | 0.070 |
Why?
|
| Circadian Rhythm | 2 | 2006 | 218 | 0.070 |
Why?
|
| Immersion | 1 | 2006 | 10 | 0.070 |
Why?
|
| Pituitary Gland | 1 | 2006 | 29 | 0.070 |
Why?
|
| Self Medication | 1 | 2006 | 25 | 0.070 |
Why?
|
| Phenotype | 5 | 2007 | 947 | 0.070 |
Why?
|
| Adrenal Glands | 1 | 2006 | 46 | 0.070 |
Why?
|
| Synapses | 1 | 2009 | 222 | 0.070 |
Why?
|
| Cyclazocine | 2 | 1984 | 2 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2007 | 304 | 0.070 |
Why?
|
| Thermosensing | 1 | 2006 | 10 | 0.070 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2006 | 109 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2007 | 115 | 0.070 |
Why?
|
| Rats | 5 | 2009 | 5300 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2006 | 78 | 0.070 |
Why?
|
| Phenazocine | 2 | 1984 | 2 | 0.070 |
Why?
|
| Neuronal Plasticity | 1 | 2009 | 274 | 0.070 |
Why?
|
| Genome, Human | 1 | 2005 | 62 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2009 | 506 | 0.060 |
Why?
|
| Survivors | 1 | 2007 | 256 | 0.060 |
Why?
|
| Amygdala | 2 | 2018 | 159 | 0.060 |
Why?
|
| Clinical Protocols | 2 | 2016 | 172 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 438 | 0.060 |
Why?
|
| Acute Disease | 3 | 2006 | 658 | 0.060 |
Why?
|
| Marital Status | 2 | 2003 | 65 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1615 | 0.060 |
Why?
|
| Health Services | 1 | 2005 | 87 | 0.060 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 123 | 0.060 |
Why?
|
| Medication Adherence | 2 | 2021 | 335 | 0.060 |
Why?
|
| Nuclear Family | 3 | 2008 | 16 | 0.060 |
Why?
|
| Bias | 2 | 2022 | 148 | 0.060 |
Why?
|
| Defense Mechanisms | 1 | 2003 | 14 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2020 | 392 | 0.060 |
Why?
|
| Bupropion | 1 | 2004 | 63 | 0.060 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 15 | 0.060 |
Why?
|
| Medical Records | 1 | 2004 | 121 | 0.060 |
Why?
|
| Linkage Disequilibrium | 3 | 2008 | 91 | 0.050 |
Why?
|
| Conduct Disorder | 1 | 2003 | 14 | 0.050 |
Why?
|
| Delusions | 2 | 1994 | 20 | 0.050 |
Why?
|
| Intelligence Tests | 1 | 2003 | 32 | 0.050 |
Why?
|
| Human Growth Hormone | 1 | 2003 | 20 | 0.050 |
Why?
|
| Prolactin | 1 | 2003 | 61 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2005 | 1330 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2004 | 206 | 0.050 |
Why?
|
| Acupuncture, Ear | 1 | 2002 | 4 | 0.050 |
Why?
|
| Curriculum | 2 | 2019 | 575 | 0.050 |
Why?
|
| Psychophysiologic Disorders | 1 | 2002 | 20 | 0.050 |
Why?
|
| Anger | 1 | 2002 | 47 | 0.050 |
Why?
|
| Tyrosine | 2 | 1999 | 196 | 0.050 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2004 | 152 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2006 | 706 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2003 | 117 | 0.050 |
Why?
|
| Dioxoles | 1 | 1982 | 8 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2001 | 274 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 2550 | 0.050 |
Why?
|
| Saimiri | 4 | 1982 | 8 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2002 | 93 | 0.050 |
Why?
|
| Dioxolanes | 1 | 1982 | 8 | 0.050 |
Why?
|
| Software | 2 | 2016 | 418 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2017 | 2358 | 0.050 |
Why?
|
| Mentors | 1 | 2022 | 81 | 0.050 |
Why?
|
| HIV | 1 | 2021 | 56 | 0.050 |
Why?
|
| Piperidines | 1 | 1982 | 123 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2001 | 80 | 0.050 |
Why?
|
| Cyclohexanols | 1 | 2001 | 12 | 0.050 |
Why?
|
| Social Adjustment | 2 | 1999 | 74 | 0.050 |
Why?
|
| Opiate Alkaloids | 1 | 2020 | 6 | 0.050 |
Why?
|
| Paroxetine | 1 | 2001 | 28 | 0.050 |
Why?
|
| Spouse Abuse | 1 | 2001 | 40 | 0.050 |
Why?
|
| Schizophrenic Psychology | 2 | 1991 | 53 | 0.050 |
Why?
|
| Rest | 1 | 2020 | 78 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2020 | 39 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2001 | 289 | 0.050 |
Why?
|
| Contact Tracing | 1 | 2020 | 7 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 197 | 0.040 |
Why?
|
| Heterosexuality | 1 | 2020 | 17 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2002 | 311 | 0.040 |
Why?
|
| Cyclohexylamines | 1 | 1980 | 1 | 0.040 |
Why?
|
| Psychoses, Alcoholic | 1 | 1999 | 5 | 0.040 |
Why?
|
| Emergency Services, Psychiatric | 1 | 1999 | 18 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2000 | 64 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2000 | 55 | 0.040 |
Why?
|
| Professional Role | 1 | 2020 | 80 | 0.040 |
Why?
|
| Registries | 1 | 2003 | 733 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2000 | 40 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 306 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2013 | 880 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 1980 | 173 | 0.040 |
Why?
|
| Cannabidiol | 1 | 1980 | 31 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1999 | 37 | 0.040 |
Why?
|
| Family Therapy | 1 | 2000 | 82 | 0.040 |
Why?
|
| Transaminases | 1 | 1999 | 21 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 1999 | 649 | 0.040 |
Why?
|
| Stroke | 1 | 2012 | 2163 | 0.040 |
Why?
|
| Social Behavior Disorders | 1 | 1999 | 16 | 0.040 |
Why?
|
| Immunoglobulin Fragments | 1 | 1999 | 14 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2000 | 157 | 0.040 |
Why?
|
| Stereoisomerism | 4 | 1984 | 169 | 0.040 |
Why?
|
| Dronabinol | 1 | 1980 | 84 | 0.040 |
Why?
|
| Glycopeptides | 1 | 1999 | 15 | 0.040 |
Why?
|
| Estradiol | 1 | 2020 | 176 | 0.040 |
Why?
|
| Documentation | 2 | 2013 | 83 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 1999 | 114 | 0.040 |
Why?
|
| Psychological Techniques | 1 | 2018 | 17 | 0.040 |
Why?
|
| Disease Progression | 2 | 1999 | 1038 | 0.040 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2018 | 27 | 0.040 |
Why?
|
| Receptors, Opioid | 3 | 1984 | 60 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 445 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 158 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Communication | 1 | 2020 | 329 | 0.040 |
Why?
|
| Incidence | 3 | 2008 | 1603 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 1997 | 36 | 0.040 |
Why?
|
| Plasma Cells | 1 | 1997 | 19 | 0.040 |
Why?
|
| District of Columbia | 1 | 2017 | 23 | 0.040 |
Why?
|
| Baltimore | 1 | 2017 | 34 | 0.040 |
Why?
|
| Pedigree | 2 | 2008 | 159 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 2 | 1988 | 57 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 91 | 0.040 |
Why?
|
| Rats, Inbred Strains | 4 | 1984 | 532 | 0.040 |
Why?
|
| Self-Help Groups | 2 | 2008 | 38 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 742 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2017 | 38 | 0.040 |
Why?
|
| Bone Marrow | 1 | 1997 | 168 | 0.040 |
Why?
|
| Heroin | 1 | 2017 | 49 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2017 | 96 | 0.030 |
Why?
|
| Family | 2 | 2009 | 293 | 0.030 |
Why?
|
| Motor Activity | 1 | 1980 | 621 | 0.030 |
Why?
|
| New South Wales | 1 | 2016 | 10 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 413 | 0.030 |
Why?
|
| Macaca mulatta | 3 | 1982 | 77 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.030 |
Why?
|
| Smokers | 1 | 2018 | 200 | 0.030 |
Why?
|
| Borderline Personality Disorder | 1 | 1996 | 13 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 281 | 0.030 |
Why?
|
| Preventive Psychiatry | 1 | 2015 | 3 | 0.030 |
Why?
|
| New Zealand | 1 | 2015 | 28 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 278 | 0.030 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2015 | 11 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2015 | 69 | 0.030 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2015 | 57 | 0.030 |
Why?
|
| Lead | 1 | 1975 | 45 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 100 | 0.030 |
Why?
|
| North Carolina | 1 | 2015 | 224 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1999 | 1083 | 0.030 |
Why?
|
| Unemployment | 1 | 2015 | 18 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 59 | 0.030 |
Why?
|
| Puerperal Disorders | 1 | 1995 | 20 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 152 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 1994 | 31 | 0.030 |
Why?
|
| Parahippocampal Gyrus | 1 | 2014 | 15 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 1999 | 1447 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2016 | 113 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 267 | 0.030 |
Why?
|
| Globus Pallidus | 1 | 2014 | 64 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 492 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 718 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 82 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 242 | 0.030 |
Why?
|
| Tryptophan | 2 | 1999 | 65 | 0.030 |
Why?
|
| Child Abuse, Sexual | 1 | 1995 | 150 | 0.030 |
Why?
|
| Liver | 1 | 1999 | 1118 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 64 | 0.030 |
Why?
|
| Patient Admission | 1 | 1994 | 99 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2015 | 307 | 0.030 |
Why?
|
| Comprehension | 1 | 2013 | 71 | 0.030 |
Why?
|
| Health Literacy | 1 | 2013 | 63 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 420 | 0.030 |
Why?
|
| Volition | 1 | 2012 | 16 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2013 | 240 | 0.030 |
Why?
|
| Alanine | 1 | 1992 | 38 | 0.030 |
Why?
|
| Naloxone | 2 | 1982 | 56 | 0.030 |
Why?
|
| Hallucinations | 1 | 1991 | 19 | 0.030 |
Why?
|
| Causality | 2 | 2006 | 82 | 0.030 |
Why?
|
| Stereotyped Behavior | 1 | 1991 | 42 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2013 | 230 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 622 | 0.020 |
Why?
|
| Beer | 1 | 2011 | 6 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 1991 | 187 | 0.020 |
Why?
|
| Seizures | 1 | 2013 | 279 | 0.020 |
Why?
|
| Reinforcement Schedule | 2 | 1982 | 59 | 0.020 |
Why?
|
| Psychiatric Department, Hospital | 1 | 1991 | 17 | 0.020 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1990 | 8 | 0.020 |
Why?
|
| Computer Systems | 1 | 2010 | 42 | 0.020 |
Why?
|
| Homeostasis | 1 | 2012 | 291 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 56 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Penetrance | 1 | 2010 | 17 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 119 | 0.020 |
Why?
|
| Health Behavior | 1 | 2013 | 458 | 0.020 |
Why?
|
| Body Image | 1 | 1990 | 100 | 0.020 |
Why?
|
| Family Relations | 1 | 2009 | 47 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1999 | 420 | 0.020 |
Why?
|
| Domestic Violence | 1 | 2009 | 36 | 0.020 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1989 | 25 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1989 | 30 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 1989 | 22 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1992 | 296 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Population | 1 | 2009 | 11 | 0.020 |
Why?
|
| Occupations | 1 | 2009 | 27 | 0.020 |
Why?
|
| Thyrotropin | 1 | 1989 | 49 | 0.020 |
Why?
|
| Personality Assessment | 2 | 2001 | 71 | 0.020 |
Why?
|
| Thyrotoxicosis | 1 | 1988 | 4 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 35 | 0.020 |
Why?
|
| Thyroxine | 1 | 1989 | 62 | 0.020 |
Why?
|
| Dopamine | 1 | 2011 | 474 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 240 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 144 | 0.020 |
Why?
|
| Antibody Specificity | 2 | 1999 | 98 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 334 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 301 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1988 | 64 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 208 | 0.020 |
Why?
|
| Swimming | 2 | 1980 | 38 | 0.020 |
Why?
|
| Bulimia | 1 | 1988 | 72 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2008 | 260 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 507 | 0.020 |
Why?
|
| Lod Score | 1 | 2006 | 14 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 1 | 2006 | 35 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2006 | 50 | 0.020 |
Why?
|
| Introns | 1 | 2006 | 68 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 770 | 0.020 |
Why?
|
| Visual Perception | 1 | 2007 | 124 | 0.020 |
Why?
|
| Terminology as Topic | 2 | 1999 | 141 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 40 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2008 | 294 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2005 | 161 | 0.020 |
Why?
|
| Hydromorphone | 1 | 1984 | 14 | 0.010 |
Why?
|
| Models, Molecular | 2 | 1999 | 546 | 0.010 |
Why?
|
| Community Health Services | 1 | 2004 | 141 | 0.010 |
Why?
|
| Mice | 3 | 1999 | 8474 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 378 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1999 | 481 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2001 | 53 | 0.010 |
Why?
|
| Neurobiology | 1 | 2001 | 9 | 0.010 |
Why?
|
| Ritanserin | 1 | 2001 | 5 | 0.010 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2001 | 8 | 0.010 |
Why?
|
| Serotonin Agents | 1 | 2001 | 13 | 0.010 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2001 | 42 | 0.010 |
Why?
|
| Sodium Oxybate | 1 | 2001 | 13 | 0.010 |
Why?
|
| Adolescent Psychiatry | 1 | 2000 | 5 | 0.010 |
Why?
|
| Binding Sites | 1 | 1982 | 631 | 0.010 |
Why?
|
| Child Psychiatry | 1 | 2000 | 5 | 0.010 |
Why?
|
| Institutionalization | 1 | 2000 | 7 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 94 | 0.010 |
Why?
|
| Geriatric Psychiatry | 1 | 2000 | 9 | 0.010 |
Why?
|
| Conization | 1 | 2000 | 3 | 0.010 |
Why?
|
| Uterine Cervicitis | 1 | 2000 | 18 | 0.010 |
Why?
|
| Corticosterone | 1 | 1980 | 51 | 0.010 |
Why?
|
| Haplorhini | 1 | 1980 | 44 | 0.010 |
Why?
|
| Self Administration | 1 | 1982 | 419 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1980 | 75 | 0.010 |
Why?
|
| Body Weight | 2 | 1988 | 554 | 0.010 |
Why?
|
| Food, Fortified | 1 | 1980 | 38 | 0.010 |
Why?
|
| Vagina | 1 | 2000 | 88 | 0.010 |
Why?
|
| Public Health | 1 | 2001 | 201 | 0.010 |
Why?
|
| Antibodies, Bispecific | 1 | 1999 | 12 | 0.010 |
Why?
|
| Titrimetry | 1 | 1999 | 11 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 99 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 1999 | 27 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 272 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1999 | 165 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 231 | 0.010 |
Why?
|
| Behavioral Symptoms | 1 | 1999 | 32 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 1999 | 99 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1999 | 112 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1999 | 65 | 0.010 |
Why?
|
| Epitopes | 1 | 1999 | 146 | 0.010 |
Why?
|
| Glycosylation | 1 | 1999 | 185 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 123 | 0.010 |
Why?
|
| Thermodynamics | 1 | 1999 | 162 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 1998 | 13 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1998 | 26 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1999 | 362 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2000 | 453 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 852 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1999 | 346 | 0.010 |
Why?
|
| Temperature | 1 | 1999 | 341 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1999 | 618 | 0.010 |
Why?
|
| Diet | 1 | 1980 | 514 | 0.010 |
Why?
|
| Health Education | 1 | 1999 | 279 | 0.010 |
Why?
|
| Escape Reaction | 1 | 1975 | 10 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1999 | 332 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1995 | 80 | 0.010 |
Why?
|
| Irritable Mood | 1 | 1994 | 15 | 0.010 |
Why?
|
| Lactation | 1 | 1975 | 110 | 0.010 |
Why?
|
| Electroconvulsive Therapy | 1 | 1999 | 402 | 0.010 |
Why?
|
| Heroin Dependence | 1 | 1993 | 23 | 0.010 |
Why?
|
| Syndrome | 1 | 1994 | 255 | 0.010 |
Why?
|
| Plasminogen | 1 | 1992 | 28 | 0.010 |
Why?
|
| Fibrin | 1 | 1992 | 35 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1992 | 55 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 1992 | 147 | 0.010 |
Why?
|
| Plasma | 1 | 1992 | 58 | 0.010 |
Why?
|
| Protein Engineering | 1 | 1992 | 35 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1992 | 87 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 204 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1992 | 152 | 0.010 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 1 | 1988 | 2 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 2455 | 0.010 |
Why?
|
| Serotonin | 1 | 1988 | 144 | 0.000 |
Why?
|
| Lung | 1 | 1988 | 849 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1984 | 765 | 0.000 |
Why?
|
| Myocardium | 1 | 1988 | 1204 | 0.000 |
Why?
|